LY 290181

Drug Profile

LY 290181

Latest Information Update: 30 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Anti-ischaemics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Naphthalenes; Pyrans; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Metalloprotease inhibitors; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetic angiopathies; Ischaemic heart disorders; Rheumatic disorders

Most Recent Events

  • 09 Mar 1999 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
  • 24 Oct 1996 Preclinical development for Ischaemic heart disorders in USA (Unknown route)
  • 18 Sep 1996 LY 290181 failed to pass through 2-week toxicology studies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top